Bolt Metals Corp is engaged in the acquisition and exploration of mineral exploration and evaluation assets in Indonesia. The company owns a nickel project named Cyclops located in Indonesia. It operates in a single reportable operating segment the Acquisition and exploration of exploration and evaluation assets located in Indonesia and Canada.
相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
进行中（未招募）
1
20.0%
招募中
1
20.0%
终止
3
60.0%
暂无批准数据
- Nurix Therapeutics has appointed Wes Burwell as its new Chief Human Resources Officer, effective August 20, 2026, as the company advances its late-stage clinical pipeline and prepares for commercialization. - Mr. Burwell brings more than 20 years of human resources leadership experience in life sciences, including roles at Bolt Biotherapeutics and Global Blood Therapeutics. - The appointment supports Nurix's evolution from a research and early clinical-stage company into a fully integrated biopharmaceutical organization focused on targeted protein degradation medicines. - Nurix's pipeline includes bexobrutideg (a BTK degrader co-developed with Roche), NX-1607 (a CBL-B inhibitor), and degraders of IRAK4 and STAT6 in collaboration with Gilead and Sanofi.
- DelveInsight's 2025 pipeline report reveals over 200 companies developing 220+ therapeutic candidates for gastric cancer treatment across all clinical stages. - Recent clinical developments include Bold Therapeutics' Phase 1b/2a study of BOLD-100 with FOLFOX chemotherapy and Jazz Pharmaceuticals' zanidatamab combination trials. - Leading pipeline candidates include tislelizumab (BeiGene), catumaxomab (Linton Pharm), and tivumecirnon (RAPT Therapeutics) targeting various mechanisms from PD-1 inhibition to regulatory T cell migration. - The pipeline encompasses diverse therapeutic approaches including monoclonal antibodies, small molecules, and combination therapies targeting novel mechanisms like Claudin 18.2 and DKK1 signaling.
